Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

January 19, 2024

https://www.globenewswire.com/news-release/2024/01/05/2804866/0/en/Barinthus-Bio-Provides-a-Financial-Update-and-Announces-Anticipated-2024-Corporate-Milestones.html

OXFORD, United Kingdom, Jan. 05, 2024 (GLOBE NEWSWIRE) — Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, today provided a preliminary financial update and announced its 2024 corporate objectives. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer.

Read more at globenewswire.com

Related news for (BRNS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.